UPLC-MS/MS-based plasma lipidomics reveal a distinctive signature in systemic lupus erythematosus patients

Jiaxi Chen  |  Chong Liu  |  Shenyi Ye  |  Ruyue Lu  |  Hongguo Zhu  |  Jiaqin Xu

Taizhou Hospital of Zhejiang Province Affiliated to Wenzhou Medical University, Taizhou, China

Correspondence
Ruyue Lu, Hongguo Zhu, and Jiaqin Xu, Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University, Taizhou 318050, China. Email: lur@enzemed.com; zhuhg@enzemed.com; xujq@enzemed.com

Funding information
National Natural Science Foundation of China, Grant/Award Number: 81802078; Zhejiang Province Analysis Test Project Foundation, Grant/Award Number: 2018C37032; Basic Public Welfare Research Project of Zhejiang Province, Grant/Award Number: GF201H200021; Medical Science and Technology Project of Zhejiang Province, Grant/Award Numbers: 2018KY912, 2019RC315, 2019323341, 2020KY371; Luqiao Science and Technology Bureau Foundation, Grant/Award Number: 2017A23005

Abstract
Global lipidomics is of considerable utility for exploring altered lipid profiles and unique diagnostic biomarkers in diseases. We aim to apply ultra-performance liquid chromatography-tandem mass spectrometry to characterize the lipidomics profile in systemic lupus erythematosus (SLE) patients and explore the underlying pathogenic pathways using the lipidomics approach. Plasma samples from 18 SLE patients, 20 rheumatoid arthritis (RA) patients, and 20 healthy controls (HC) were collected. A total of 467 lipids molecular features were annotated from each sample. Orthogonal partial least square-discriminant analysis, K-mean clustering analysis and Kyoto Encyclopedia of Genes and Genomes pathway analysis indicated disrupted lipid metabolism in SLE patients, especially in phospholipid, glycerol, and sphingolipid metabolism. The area under curve (AUC) of lipid metabolism biomarkers was better than SLE inflammation markers that ordinarily used in the clinic. Proposed model of monoglyceride (MG) (16:0), MG (18:0), phosphatidylethanolamine (PE) (18:3–16:0), PE (16:0–20:4), and phosphatidylcholine (PC) (O-16:2–18:3) yielded AUC 1.000 (95% CI, 1.000–1.000), specificity 100% and sensitivity 100% in the diagnosis of SLE from HC. A panel of three lipids molecular PC (18:3-18:1), PE (20:3–18:0), PE (16:0–20:4) permitted to accurately diagnosis of SLE from RA, with AUC 0.921 (95% CI, 0.828–1.000), 70% specificity, and 100% sensitivity. The plasma lipidomics signatures could serve as an efficient and accurate tool for early diagnosis and provide unprecedented insight into the pathogenesis of SLE.

KEYWORDS
biomarkers, lipidomics, systemic lupus erythematosus

1 | INTRODUCTION

Systemic lupus erythematosus (SLE) is a complex autoimmune inflammation disease, associated with complement dysregulation, interferon activation, and immune complexes deposited in multiple organs such as skin, joints, blood vessels, and kidney. SLE develops with an incidence of 7.4–159.4 cases per 100,000 individuals worldwide and affects women at childbearing age predominantly. Unfortunately, SLE is difficult to diagnose, check or treat,
and there is no specific cure for this disease, only drugs that relieve symptoms and slow down the disease progression.\textsuperscript{5} Anti-double stranded DNA antibody showed high specificity (92\%–96\%), but sensitivity is very moderate for SLE (only 57\%–67\%).\textsuperscript{6} Therefore, identification of SLE early diagnostic biomarkers and making it a useful new tool are unmet medical needs. Lipid molecules play an important role in the energy storage and the formation of membrane structures and serve as secondary messengers in signaling that affect cell proliferation, signal transduction, and apoptosis.\textsuperscript{7,8} Previous lipidomic studies have shown the potential of plasma lipidomic profiling in the diagnosis of cancers,\textsuperscript{9} type 2 diabetes,\textsuperscript{10} cardiovascular disease,\textsuperscript{11} and so on. However, few reports exist at present regarding the quantification of lipid molecules and large-scale profiling and involve comprehensively studying lipid pathways and statistical analysis in SLE.

Due to the enhanced separation efficiency, ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) was considered as the appropriate technique for large-scale lipidomics study. As the common pathogenesis and genome-wide association studies (GWASs) revealed some common single nucleotide polymorphisms related to both rheumatoid arthritis (RA) and SLE.\textsuperscript{12,13} We compared SLE patients with RA patients and healthy controls (HCs) in our study to explore whether plasma lipidomics will provide valuable information regarding the potential diagnostic biomarkers as well as the physiology in SLE.

2 \| RESULTS

2.1 \| Characteristics of participants

The clinical features and demographic of the study cohort are summarized in Table 1. Comparisons data of gender, age, and BMI were not significantly different between the three groups ($p > 0.05$). Comparisons data of the biochemical and immunity indicated higher levels of antistreptolysin O, and dsDNA in SLE patients.

2.2 \| Comparative plasma lipid metabolomic profiles and pathway analysis between SLE patients and HCs

A total of 467 lipids in plasma were identified in both patients and healthy cohorts. The supervised orthogonal partial least square-discriminant analysis (OPLS-DA) model revealed a clear segmentation between SLE patients and HCs (Figure 1A). The verification results of the permutation test to the OPLS-DA model showed that R2X was 0.463, R2Y was 0.929, and Q2 was 0.782 respectively ($p < 0.005$) (Figure 1C). Differential lipids were screened by using a fold change $> 1.2$ or $< 1/1.2$, and variable importance projection (VIP) $\geq 1.0$, were showed in the volcano plot (Figure 1E). A total of 191 lipids had significantly changed in SLE patients versus HCs, of which 157 upregulated and 34 downregulated lipids. The area under curve (AUC) of 22 lipids was higher than 0.85. Among them, 19 lipids were upregulated, and four lipids were downregulated. Monoglyceride (MG) (16:0) decreased significantly in SLE patients, with the AUC area 0.997, specificity 95\% and sensitivity 100\%, respectively (Table 2).

Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis was used to check the lipid metabolomic pathways that were affected in SLE patients. The differential metabolites are enriched in the following pathways, such as vitamin digestion absorption, thermogenesis, regulation of lipolysis in adipocytes, metabolic pathways, insulin resistance, glycerolipid metabolism, fat digestion and absorption, and cholesterol metabolism (Figures 2A and 2B).
2.3 Comparative plasma lipid metabolomic profiles and pathway analysis between SLE and RA patients

The supervised OPLS-DA model revealed a clear segmentation between RA and SLE patients (Figure 1B). Specifically, OPLS-DA verification chart revealed the prediction ability of the model (Q2), goodness of fit (R2X and R2Y) were 0.589, 0.555 and 0.989, respectively (Figure 1D). Differential lipids were screened by using a fold change > 1.2 or < 1/1.2, and VIP ≥ 1.0 and showed in the volcano plot (Figure 1F). Based on this standard, a total of 164 differentially lipid metabolomics were identified between RA and SLE patients (including 156 upregulated and eight downregulated lipids). The AUC scores of 14 lipids panel were significantly higher than 0.8. Among them, phosphatidylcholine (PC) (18:3–18:1) could be used for accurately diagnosis of RA from SLE, with 0.897 AUC, 80% specificity and 95% sensitivity (Table 3).

KEGG pathways analysis between RA and SLE patients was also carried out, and following lipid metabolic pathways were changed such as metabolic pathways, glycerophospholipid metabolism, retrograde endocannabinoid signaling, insulin resistance, glycerolipid metabolism, fat digestion and absorption, and cholesterol metabolism (Figures 2C and 2D).

2.4 Characterized lipidomics profile in SLE patients

The 191 plasma lipid metabolomics which have changed in SLE patients versus HCs were clustered by using k-means (n = 2). In this trial, 34 lipids formed cluster 1, and when compared with HCs, their content in SLE and RA patients has a significant downward trend (Figure 3A); 157 lipids formed cluster 2, and only their content in SLE patients showed a significant upward trend when compared with HCs; however the upward trend in RA patients was unobvious (Figure 3B). In our results, the lipids of cluster 1 and cluster 2 were mainly enriched in the three pathways: triglyceride (TG) metabolism, glycerophospholipid metabolism, and sphingolipid metabolism.

Our results showed that individuals with SLE and RA had significantly lower levels of MG and free fatty acids when have compared with HCs. We also found significantly higher levels of TGs and diglyceride (DG) only in SLE individuals (Figure 3C). Further analysis showed that both the levels of lysophosphatidylethanolamine, PC, PE in glycerol-phospholipids metabolism and sphingomyelin (SM), ceramide levels in sphingolipids metabolism were much higher in SLE individuals, while in RA individuals, the increase was much lower, or the level was similar to HCs (Figures 3D and 3E).
FIGURE 2 The lipidome KEGG enrichment analysis of SLE patients. (A and C) KEGG pathway analysis of differentially expressed lipids between SLE and HC groups. (B and D) KEGG pathway analysis of differentially expressed lipids between SLE and RA groups. The color of bubbles represents the value of adjusted p-value, and the size of bubbles represents the number of counts.

2.5 Evaluation of lipid markers on SLE

Receiver operating characteristic (ROC) curve was used to evaluate the ability of differential lipids in the diagnosis of SLE patients from RA patients and HCs. The panel of these five differential lipids including MG (16:0), MG (18:0), PE (18:3–16:0), PE (16:0–20:4), and PC (O-16:2–18:3), has a great potential to distinguish the SLE patients from HC group, with AUC 1.000 (95% CI, 1.000–1.000), specificity 100%, and sensitivity 100% (Figure 4A). Furthermore, the panel of the three differential lipids including PC (18:3–18:1), PE (20:3–18:0), and PE (16:0–20:4) can well distinguish SLE patients from RA patients, with AUC 0.921 (95% CI, 0.828–1.000), 70% specificity, and 100% sensitivity (Figure 4B).

Lipid metabolism biomarkers MG (16:0), MG (18:0), and PC (O-16:2–18:3) were not associated with SLE disease activity index (SLEDAI) score \(p > 0.05\); however, PE (18:3–16:0) and PE (16:0–20:4) were higher in SLEDAI score > 11 group (Figure 5).

3 DISCUSSION

The landscape of current SLE candidate biomarkers is relatively narrow. Therefore, the identification and application of SLE early diagnosis biomarkers are an unmet medical need. Through lipidomic approaches by using UPLC-MS/MS, it is possible to quantify and identify the level of lipid molecular species, useful to identify biomarkers and to better understand the pathophysiology of SLE. In this study, we described a comprehensive evaluation and revealed a significant lipidomic pattern in SLE patients, with significant changes mainly in phospholipids metabolism, sphingolipids metabolism, and TGs metabolism.

Our results showed dysfunctional sphingolipids metabolism related to the SLE pathophysiology, as the plasma levels of many Ceramide (Cer) and SM increased significantly. Sphingolipids were potential biomarkers for hepatitis B virus (HBV) infection, Type I diabetes, and Parkinson’s disease. However, the function of
sphingolipids in SLE was unclear. Previous reports illustrated that increased circulating sphingolipids were associated with SLE clinical disease activity. Recently, Lu et al identified SM with N18:0, N18:1, and N22:0 increased; however, ceramides with N22:0, N23:0, and N24:0 decrease in SLE patients when compared to the HC group. Studies proved that many sphingolipids elevated in SLE patients’ kidneys and inhibition of sphingolipids synthase could reverse these experimental models. Besides, sphingolipid-metabolizing enzymes-targeted therapies are now used to inhibit autoimmune diseases such as psoriasis and multiple sclerosis. We believe that modulating the sphingolipid pathway might be useful for the future development of therapies given to SLE patients.

Glycerophospholipids contain many derivative forms, which are structural components of cell membranes. Our present results observed upregulated levels of certain glycerophospholipids in SLE patients. The lipids with the most robust differences are shown in PC (18:3–18:1), PE (20:3–18:0), and PE (16:0–20:4), while in RA patients, these levels were similar to healthy subjects, so they permitted to accurately diagnosis of RA from SLE and yielded a classification performance AUC of 0.921. In addition, we found PE (18:3–16:0) and PE (16:0–20:4) were higher in SLEDAI score > 11 group, which might be the important biomarkers for the early diagnosis, prognosis, and treatment of SLE, but further research is needed. Two previous research centers have reported different results, as Hu et al identified PE (16:0–18:1), (16:0–20:4), (18:0–20:4), (18:0–22:4), (18:0–22:5), PC (18:0–18:0), and (16:0–18:2) decreased significantly; however, Lu et al identified PE species (16:0–18:2), (18:0–18:2), (18:1–18:2), (16:0–22:6), and (18:0–22:6) increased significantly in SLE patients. Glycerophospholipids are an important part of cell membrane; therefore, these alterations might be associated with changes of lymphocytes.
Our results gathered herein showed the decrease of some fatty acids and significantly reduction of MG in fat metabolism for SLE patients. Besides, our results also observed the increase of some TG, DG suggests dysfunctional of TGs metabolism. Plasma MG (18:0) and MG (16:0) in both RA and SLE patients decreased significantly. To the best of our knowledge, little information is available on the signaling role of MG and its physiological significance. Monoacylglycerol lipase (MGL) and ABHD6 are the mainly rate-limiting enzymes that degrade MGs. MGL hydrolyses TGs or phospholipids into fatty acids and MGs and then regulates lipid accumulation follows inflammation, oxidative stress. Some previous reports have demonstrated the critical role of MGL in cancer development. However, little is known about the role of MGL in SLE. Besides, ABHD6 is also an important contributor to hydrolyses TGs or phospholipids into fatty acids and MGs. Recent GWASs have revealed a robust correlation between ABHD6 and SLE susceptibility. From our point of view, there might be some possible correlations between the apparent lack of MGs or fatty acids in vivo and enhanced expression of ABHD6 gene in SLE. However, these speculations need to be confirmed by further clinical and biochemical study.

In summary, our large-scale work makes a step forward in demonstrating the clinical utility of lipidomics signature to assist potentially early diagnosis and treatment SLE. Proposed model of MG (16:0), MG (18:0), PE (18:3–16:0), PE (16:0–20:4) and PC (O-16:2–18:3) seemed to be ideal for early diagnosis of SLE. Significant changes of lipidomic pattern in phospholipids, sphingolipids and TGs metabolism may reflect some pathological processes or may appear due to ongoing inflammation and damage in the development of SLE. Further validation would be conducted to identify their precise functions on a larger population.

4 | MATERIAL AND METHODS

4.1 | Ethical compliance and samples

Ethics approval was obtained from the Ethics Committee of Taizhou Hospital of Zhejiang Province. All the investigation protocols were carried out in accordance with the relevant guidelines and complied with the principles of the Declaration of Helsinki. Written informed consent was achieved from each participant for their blood to be used for this research.

Between May 2019 and October 2019, 18 SLE patients, 20 RA patients, and 20 healthy subjects matched for gender, age, and ethnicity were recruited from Taizhou Hospital of Zhejiang Province. The diagnosis for RA and SLE patients was strictly according to the criteria, and their clinical information on gender, age, BMI, and laboratory inflammation indicators was available. We
used rigorous inclusion criteria for HCs with no cardiovascular, tumors, immunity, or other known infection diseases.

Approximately 2 ml EDTA anticoagulated blood was collected from every subject under fasting conditions. The plasma samples were immediately stored at -80°C after centrifugation for further UPLC-MS/MS processing and analysis.

**4.2 Lipidomics analyses**

Firstly, the plasma samples were thawed at room temperature, vortexed for 10 s, and centrifuged at 3000 rpm for 5 min at 4°C. Secondly, transfer 50 ul of sample per tube to a new EP tube, mix with 1 mL of lipid extraction solution, and vortex for 2 min. Thirdly, the ultrasound tube was sonicated for 5 min, mixed with 500 uL of water, vortexed for 1 min, and centrifuged at 12000 g at 4°C for 10 min. Then collect 500 ul of supernatant and dry with nitrogen, reconstitute with 100 ul of mobile phase B. The sample was vortexed for 1 min and then centrifuged at 14000 g at 4°C for 15 min. Finally, the samples were analyzed by UPLC-MS/MS.

The calibration and quality control (QC) samples were prepared with the mixed plasma of subjects prior to sample analysis. Every 10 samples to be analyzed were separated by one QC sample for the duration of the detection to monitor repeatability during the analysis. The high overlaps of the total ion flow between different QC samples, that is, the retention time and peak strength are consistent, indicate that the signal stability of the mass spectrum is good at different times.

**4.3 UPLC-MS/MS analysis**

The lipid metabolites of plasma samples were initially separated on an ultra-high performance liquid chromatograph (Thermo C30, i.d.2.1 × 100 mm 2.6 um columns). The column temperature was set to 45°C. The mobile phase (A) uses 60% acetonitrile in water, and the mobile phase (B) uses 10% acetonitrile in isopropanol. The elution gradient
### TABLE 2 Diagnostic capacity of the 22 selected lipid metabolites altered in SLE compared to HC

| Metabolite | SEN (%) | SPE (%) | AUC | p value | Type |
|------------|---------|---------|-----|---------|------|
| MG MG(16:0) | 100 | 95 | 0.997 | 0.000 | down |
| MG(18:0) | 94 | 80 | 0.906 | 0.000 | down |
| PE PE(18:3-16:0) | 94 | 85 | 0.944 | 0.000 | up |
| PE(16:0-20:4) | 71 | 100 | 0.926 | 0.000 | up |
| PE(16:0-18:0) | 95 | 75 | 0.882 | 0.000 | up |
| PE(18:1-16:0) | 76 | 90 | 0.879 | 0.002 | up |
| PE(20:3-16:0) | 71 | 90 | 0.873 | 0.006 | up |
| TG TG(52:0) | 100 | 80 | 0.953 | 0.000 | up |
| NL-16:0 | 82 | 95 | 0.944 | 0.000 | up |
| TG(50:0) | 100 | 80 | 0.938 | 0.000 | up |
| NL-18:0 | 100 | 70 | 0.907 | 0.000 | up |
| TG(50:3) NL-18:3 | 82 | 90 | 0.921 | 0.001 | up |
| TG(52:0) | 100 | 70 | 0.907 | 0.000 | up |
| NL-14:0 | 76 | 95 | 0.906 | 0.000 | up |
| TG(50:1) NL-16:0 | 71 | 90 | 0.901 | 0.001 | up |
| NL-16:0 | 82 | 85 | 0.888 | 0.001 | up |
| TG(56:5) NL-16:0 | 88 | 75 | 0.882 | 0.000 | up |
| TG(56:5) NL-22:4 | 96 | 60 | 0.881 | 0.000 | up |
| TG(52:1) NL-20:1 | 65 | 95 | 0.879 | 0.001 | up |
| TG(52:3) NL-18:0 | 91 | 90 | 0.873 | 0.000 | up |
| LPE LPE(24:6) | 82 | 85 | 0.903 | 0.000 | down |
| PC PC(O-16:2-18:3) | 95 | 80 | 0.997 | 0.000 | down |

**Abbreviations:** AUC, area under curve; MG, monoglyceride; LPE, lysophosphatidylethanolamine; PC, phosphatidylcholine; PE, phosphatidylethanolamine; SEN, sensitivity; SPE, specificity; TG: triglycerides. 

At 0 min is set to 20% B, the 3 min elution gradient is set to 50% B, the 9 min elution gradient is set to 75% B, and the 15 min elution gradient is set to 90% B liquid, the balance liquid is 50% B liquid, the flow rate is set to 350 ul/min, and the injection volume of sample was 2 μl.

Then initially separated sample enters the QTRAP LC-MS / MS system. The system is equipped with an ESI Turbo ion spray interface and can be operated in positive and negative ion modes. The operating parameters of the ESI source are as follows: the ion source temperature is set to 550° C; the ion spray voltage is set to 5500 V; the ion source gas I, gas II, and curtain gas are set to 55, 60, and 25 psi, and the collision gas is set to medium. Note that 10 and 100 μmol/L polypropylene glycol solutions were used for instrument tuning and PPG calibration separately. Quantitative analysis is accomplished by multiple reaction monitoring analysis. The signal intensity of characteristic ions is obtained and represents the relative content of corresponding substance. MultiQuant is used to integrate and correct chromatographic peaks.

### TABLE 3 Diagnostic capacity of the 14 selected lipid metabolites altered in SLE compared to RA

| Metabolite | SEN (%) | SPE (%) | AUC | p value | Type |
|------------|---------|---------|-----|---------|------|
| PC PC(18:3-18:1) | 95 | 80 | 0.897 | 0.000 | up |
| PC(O-12:0-14:0) | 95 | 65 | 0.859 | 0.000 | up |
| PC(O-18:3-20:2) | 100 | 60 | 0.851 | 0.000 | up |
| PC(O-18:2-18:2) | 100 | 60 | 0.821 | 0.001 | up |
| PC(O-20:3-20:2) | 95 | 60 | 0.818 | 0.001 | up |
| PC(O-18:3-18:2) | 100 | 50 | 0.803 | 0.000 | up |
| PE PE(20:3-18:0) | 88 | 85 | 0.876 | 0.000 | up |
| PE(16:0-20:4) | 85 | 80 | 0.864 | 0.002 | up |
| PE(18:0-20:4) | 76 | 90 | 0.797 | 0.002 | up |
| PE(18:3-16:0) | 94 | 50 | 0.794 | 0.004 | up |
| SM SM(d18:2/22:1) | 88 | 75 | 0.865 | 0.000 | up |
| DG DG(16:1-18:3) | 76 | 85 | 0.851 | 0.000 | up |
| LPC LPC(20:4) | 76 | 85 | 0.838 | 0.001 | up |
| TG TG(52:0) | 76 | 80 | 0.801 | 0.025 | up |

| Metabolite | SEN (%) | SPE (%) | AUC | p value | Type |
|------------|---------|---------|-----|---------|------|
| PC PC(O-16:2-18:3) | 95 | 80 | 0.897 | 0.000 | down |

**Abbreviations:** AUC, area under curve; DG, diacylglycerol; LPC, lysophosphatidylcholine; PC, phosphatidylcholine; PE, phosphatidylethanolamine; SEN, sensitivity; SM, sphingolipid; SPE, specificity; TG, triglycerides. 

“:”, carbons and double bonds; “-”, fatty acyle constituents; “/”, positional isomers.

### 4.4 Statistical analysis

The software Analyst 1.6.3 was used to process the mass spectrometry data. The classification and naming of lipids are strictly in accordance with LIPID MAPS convention (www.lipidmaps.org). The baseline characteristics of the study population were evaluated by chi-square test and Kruskal-Wallis H test. MetaboAnalyst 4.0 (http://www.metaboanalyst.ca) was applied to analyze the metabolite OPLS model. R2X (the interpretability of the model for the categorical variable X), R2Y (the interpretability of the model for variable Y), and Q2 (the predictability of the model) were obtained to judge the validity of OPLS model. K-means clustering method was used to screen the lipid metabolites of SLE group, RA group, and the HC group. The binary logistic regression fitting to evaluate the diagnostic value of the combined model and the MedCalc (19.0.7) software were used to draw the receiver characteristic working curve (ROC) which includes AUC value, sensitivity, and specificity.
ACKNOWLEDGMENTS
This work is funded by National Natural Science Foundation of China (grant number: 81802078), Zhejiang Province Analysis Test Project Foundation (grant number: 2018C37032), Basic Public Welfare Research Project of Zhejiang Province (grant number: GF20H200021), Medical Science and Technology Project of Zhejiang Province (grant number: 2018KY912/2019RC315/2019323341/2020KY371), and Luqiao Science and Technology Bureau Foundation (grant number: 2017A23005).

AUTHOR CONTRIBUTIONS
Jiaxi Chen conceived the idea and designed the experiments. Shenyi Ye, Xianhong Ding, and Yang Lu carried out experiments. Haiyan Lv, Xiangyu Xu, Bingjie Hu, and Chenliang Hong analyzed experimental results. Jiaxi Chen, Chong Liu, and Jiaqin Xu wrote the main manuscript. Ruyue Lu, Hongguo Zhu, and Bo Shen supervised all aspects of the study. All authors reviewed the manuscript.

CONFLICT OF INTEREST
All authors declare no competing interests.

ETHICS STATEMENT
This project was permitted by the Ethics Committee of Taizhou Hospital of Zhejiang Province. This research conforms to all the laws and ethical guidelines that apply in the country.

DATA AVAILABILITY STATEMENT
The datasets used and analyzed during the current study are available from the corresponding author upon reasonable request.

REFERENCES
1. Durcan L, O’Dwyer T, Petri M. Management strategies and future directions for systemic lupus erythematosus in adults. Lancet. 2019;393(10188):2332–2343.
2. Kaul A, Gordon C, Crow M, et al. Systemic lupus erythematosus. Nat Rev Dis Primers. 2016;2:16039.
3. Fortuna G, Brennan MT. Systemic lupus erythematosus: epidemiology, pathophysiology, manifestations, and management. Dent Clin North Am. 2013;57(4):631–665.
4. Joo YB, Bae SC. Assessment of clinical manifestations, disease activity and organ damage in 996 Korean patients with systemic lupus erythematosus: comparison with other Asian population. Int J Rheum Dis. 2015;18(2):117–128.
5. Xiong W, Lahita R. Pragmatic approaches to therapy for systemic lupus erythematosus. Nat Rev Rheumatol. 2014;10(2):97–107.
6. Cozzani E, Drosena M, Gasparini G, et al. Serology of lupus erythematosus: correlation between immunopathological features and clinical aspects. Autoimmune Dis. 2014;2014:321359.
7. Santos C, Schulze A. Lipid metabolism in cancer. FEBS J. 2012;279(15):2610–2623.
8. Ferreira H, Pereira A, Melo T, et al. Lipidomics in autoimmune diseases with main focus on systemic lupus erythematosus. J Pharm Biomed Anal. 2019;174:386–395.
9. Lee G, Lee J, Moon M. Plasma lipid profile comparison of five different cancers by nanoflow ultrahigh performance liquid chromatography-tandem mass spectrometry. Anal Chim Acta. 2019;1063:117–126.
10. Razquin C, Toledo E, Clish C, et al. Plasma lipidomic profiling and risk of type 2 diabetes in the predimed trial. Diabetes Care. 2018;41(12):2617–2624.
11. Tabassum R, Rämö J, Ripatti P, et al. Genetic architecture of human plasma lipolipase and its link to cardiovascular disease. Nat Commun. 2019;10(1):4329.
12. Wang T, Jiao Y, Zhang X. Immunometabolic pathways and its therapeutic implication in autoimmune diseases. Clin Rev Allergy Immunol. 2021;60:55–67.
13. Márquez A, Vidal B, Rodríguez R, et al. A combined large-scale meta-analysis identifies COG6 as a novel shared risk locus for rheumatoid arthritis and systemic lupus erythematosus. Ann Rheum Dis. 2017;76(1):286–294.
14. Gordon RE, Nemeth JF, Singh S, Lingham RB, Grewal IS. Harnessing SLE autoantibodies for intracellular delivery of biologic therapeutics. Trends Biotechnol. 2021;39:298–310.
15. Qu F, Zheng S, Liu S, et al. Serum sphingolipids reflect the severity of chronic HBV infection and predict the mortality of HBV-acute-on-chronic liver failure. PLoS One. 2014;9:e104988.
16. Meikle PJ, Summers SA. Sphingolipids and phospholipids in insulin resistance and related metabolic disorders. Nat Rev Endocrinol. 2017;13:79–91.
17. Guedes LC, Chan RB, Gomes MA, et al. Serum lipid alterations in GBA-associated parkinson’s disease. Parkinsonism Relat Disord. 2017;44:58–65.
18. Checa A, Idborg H, Zandian A, et al. Dysregulations in circulating sphingolipids associate with disease activity indices in female patients with systemic lupus erythematosus: a cross-sectional study. Lupus. 2017;26(10):1023–1033.
19. Lu L, Hu C, Zhao Y, et al. Shotgun lipidomics revealed altered profiles of serum lipids in systemic lupus erythematosus closely associated with disease activity. Biomolecules. 2018;8(4):105.
20. Checa A, Idborg H, Zandian A, et al. Dysregulations in circulating sphingolipids associate with disease activity indices in female patients with systemic lupus erythematosus: a cross-sectional study. Lupus. 2017;26(10):1023–1033.
21. Vaclavkova A, Chimenti S, Arenberger P, et al. Oral ponesimod therapy for systemic lupus erythematosus in female patients. J Rheumatol. 2012;39(5):977–983.
22. Brinkmann V, Billich A, Baumruker T, et al. Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis. Nat Rev Drug Discov. 2010;9(11):883–897.
23. Hu C, Zhou J, Yang S, et al. Oxidative stress leads to reduction of plasmalogen serving as a novel biomarker for systemic lupus erythematosus. Free Radical Biol Med. 2016;101:471–481.
24. Poursharifi F, Madiraju S, Pretntki M. Monocyaglycerol signalling and ABHD6 in health and disease. Diabetes Obes Metab. 2017;76-89.
25. Douglass J, Zhou Y, Wu A, et al. Global deletion of MGL in mice delays lipid absorption and alters energy homeostasis and diet-induced obesity. *J Lipid Res.* 2015;56(6):1153–1171.

26. Chon S, Douglass J, Zhou Y, et al. Over-expression of monoacylglycerol lipase (MGL) in small intestine alters endocannabinoid levels and whole body energy balance, resulting in obesity. *PLoS One.* 2012;7(8):e43962.

27. Zhang J, Liu Z, Lian Z, et al. Monoacylglycerol lipase: a novel potential therapeutic target and prognostic indicator for hepatocellular carcinoma. *Sci Rep.* 2016;6:35784.

28. Ye L, Zhang B, Seviour E, et al. Monoacylglycerol lipase (MAGL) knockdown inhibits tumor cells growth in colorectal cancer. *Cancer Lett.* 2011;307(1):6–17.

29. Oparina N, Delgado V, Martinez B, et al. PXK locus in systemic lupus erythematosus: fine mapping and functional analysis reveals novel susceptibility gene ABHD6. *Ann Rheum Dis.* 2015;74(3):e14.

30. Hochberg Mc. Updating the american college of rheumatology revised criteria for the classification of systemic lupus erythematosus. *Arthritis Rheum.* 1997;40(9):1725.

31. Aletaha D, Neogi T, Silman AJ, et al. 2010 rheumatoid arthritis classification criteria: an american college of rheumatology/european league against rheumatism collaborative initiative. *Ann Rheum Dis.* 2010;69(9):1580–1588.

**How to cite this article:** Chen J, Liu C, Ye S, Lu R, Zhu H, Xu J. UPLC-MS/MS-based plasma lipidomics reveal a distinctive signature in systemic lupus erythematosus patients. *MedComm.* 2021;2:269–278.